The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
K-Ras prenylation as a potential anticancer target
Open accessAbstract
KRAS is one of the most commonly mutated oncogene and a negative predictive factor for a number of targeted therapies. Therefore, the development of targeting strategies against mutant KRAS is urgently needed. One potential strategy involves disruption of K-Ras membrane localization, which is necessary for its proper function. In this review, we summarize the current data about the importance of membrane-anchorage of K-Ras and provide a critical evaluation of this targeting paradigm focusing mainly on prenylation inhibition. Additionally, we performed a RAS mutation-specific analysis of prenylation-related drug sensitivity data from a publicly available database (https://depmap.org/repurposing/) of three classes of prenylation inhibitors: statins, N-bisphosphonates, and farnesyl-transferase inhibitors. We observed significant differences in sensitivity to N-bisphosphonates and farnesyl-transferase inhibitors depending on KRAS mutational status and tissue of origin. These observations emphasize the importance of factors affecting efficacy of prenylation inhibition, like distinct features of different KRAS mutations, tissue-specific mutational patterns, K-Ras turnover, and changes in regulation of prenylation process. Finally, we enlist the factors that might be responsible for the large discrepancy between the outcomes in preclinical and clinical studies including methodological pitfalls, the incomplete understanding of K-Ras protein turnover, and the variation of KRAS dependency in KRAS mutant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Drug sensitivity values from PRISM repurposing primary screen of all cell lines independent of tissue of origins. Efficacy of statins, nitrogen-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed by analyzing the open access data from [52]. Drugs included for the analyses are listed in Table 2. KRAS mutant cell lines were more resistant to statins (RAS WT mean − 0.123, SEM 0.024; KRAS MUT mean – 0.176, SEM 0.040), while the opposite can be observed in response to N-bisphosphonate treatment (RAS WT mean – 0.124, SEM 0.010; KRAS MUT mean − 0.176, SEM 0.022). Statistical significance was established in p < 0.05, using two-tailed t test. Number of cell lines included in the analyses RAS WT n ~ 390; KRAS MUT n ~ 103 (there is a small variation between the numbers of cell lines with available data for the distinct drugs)](https://figures.cochat.ai/paper-figures/c50748e2be484c38b98779b080b61e84/k-ras-prenylation-as-a-potential-anticancer-target-figure-3.jpg)
![Fig. 4 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of statins, nitrogene-containing bisphosphonates, and farnesyl-transferase inhibitors on KRAS mutant cells versus RAS wild-type cell lines are showed. List of drugs included for the analyses are listed in Table 2. Interestingly, statistically significant difference could only be observed in lung cancer cell lines treated with FTis (RAS WT mean – 0.021, SEM 0.076; KRAS MUT mean – 0.385, SEM 0.117). Note the opposite trends in sensitivity between N-bisphosphonate- and FTi-treated colorectal and lung cancer cells. Statistical significance was established in p < 0.05, using two-tailed t test. n analysis was performed using the open access data of [52]. Number of cell lines included in the analyses for colorectal cancer cell lines: RAS WT n ~ 10; KRAS MUT n ~ 20; for lung adenocarcinomas: RAS WT n ~ 28; KRAS MUT n ~ 18. There is a small variation between the number of cell lines with available data for the distinct drugs](https://figures.cochat.ai/paper-figures/c3cf2021286d4a24bb401fc8973f7584/k-ras-prenylation-as-a-potential-anticancer-target-figure-4.jpg)
![Fig. 5 Drug sensitivity values from PRISM repurposing primary screen of lung and colorectal cancer cells. Efficacy of farnesyl-transferase inhibitors (tipifarnib and lonafarnib) on HRAS mutant cells versus RAS wild-type cell lines is presented. A strong tendency was observed, HRAS mutant cells were more sensitive to FTi treatment than RAS wild-type cells (RAS WT mean – 0.178, SEM 0.026; HRAS MUT mean – 0.554, SEM 0.243). p value was calculated using two-tailed t test. The open access data of [52] was used for the analysis. Number of cell lines included in the analyses: RAS WT n = 396; HRAS MUT n = 7 (created by Graphpad Prism 5 software)](https://figures.cochat.ai/paper-figures/fab2e8c3a4154f919e05a7d13c018caf/k-ras-prenylation-as-a-potential-anticancer-target-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Inhibiting plasma membrane KRAS localization using farnesyltransferase inhibitors suppressed MAPK activity, showing an antitumor effect on cancers driven by KRAS mutations43,44.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 4×
“These mutations impair the ability of GAP proteins to facilitate hydrolyses of GTP to GDP, and therefore the proteins will be constitutively in active, GTP-bound state [1].”
BackgroundInfluentialGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878 · cited 5×
“The open access data of [52] was used for the analysis.”
BackgroundMethodInfluentialThe relation between PI3K/AKT signalling pathway and cancer
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 651
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Cited by
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
The RASopathies: from pathogenetics to therapeutics
Hebron, K. E., Hernandez, E. R., & Yohe, M. E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049107 · Cited by 167
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Morofuji, Y., Nakagawa, S., Ujifuku, K., Fujimoto, T., Otsuka, K., Niwa, M., & Tsutsumi, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020151 · Cited by 184
Computational drug repurposing: approaches, evaluation of in silico resources and case studies
Tanoli, Z., Fernández‐Torras, A., Özcan, U. O., Kushnir, A., Nader, K. M., Gadiya, Y., Fiorenza, L., Ianevski, A., Vähä-Koskela, M. J. V., Miihkinen, M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01164-x · Cited by 122
Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments
Hà, N. T. T., & Lee, C. H. (2020) · Cells · doi:10.3390/cells9112352 · Cited by 79
Metadata
- Authors
- Baranyi, M., Buday, L., & Hegedűs, B.
- Affiliations
- Semmelweis University (HU)
- Institute of Molecular Life Sciences (HU)
- Ruhrlandklinik (DE)
- Corresponding author
- Hegedűs, Balázs
- Venue
- Cancer and Metastasis Reviews
- Published
- 2020-06-10
- Volume
- 39
- Issue
- 4
- Pages
- 1127-1141
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- PMC
- PMC7680335
- OpenAlex
- W3033488157
- Cited by
- 62
- References
- 94
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 13 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 4
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer and Metastasis Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Funders
- Hungarian National Research, Development and Innovation Office (NVKP-16-1-2016-0020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- KRAS, membrane anchorage, KRAS mutation, farnesyltransferase inhibitors, statins, drug repurposing, anticancer drug targets, KRAS-mutant tumors
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Protein Processing, Post-Translational, Genes, ras, Proto-Oncogene Proteins p21(ras), Prenylation, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: K-Ras prenylation as a potential anticancer target. https://app.cochat.ai/papers/10.1007/s10555-020-09902-w
- The paper
- Baranyi, M., Buday, L., & Hegedűs, B. (2020). K-Ras prenylation as a potential anticancer target. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-020-09902-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.